# Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)

> **NCT04776252** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 2000 (estimated)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** MK-8591A

## Key facts

- **NCT ID:** NCT04776252
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-09-15
- **Primary completion:** 2029-05-29
- **Final completion:** 2029-05-29
- **Target enrollment:** 2000 (ESTIMATED)
- **Last updated:** 2025-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04776252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04776252, "Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04776252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*